GlassScriptPhysician profile
Mark R Henry
NPI 1164462354
$2,036.32
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $813.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $323.30 | 2019-2020 | |
| Novo Nordisk INC | $316.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $230.65 | 2019-2020 | |
| Amgen INC. | $160.64 | 2019-2020 | |
| Allergan, INC. | $106.43 | 2019-2020 | |
| Pfizer INC. | $102.56 | 2019-2020 | |
| Amarin Pharma, INC. | $99.55 | 2019-2020 | |
| Lilly USA, LLC | $95.74 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $66.46 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $65.06 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $52.13 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.47 | 2019 | |
| Merck Sharp & Dohme LLC | $39.44 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.19 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32.01 | 2019 | |
| Genentech USA, INC. | $31.97 | 2019-2020 | |
| Neurelis, INC. | $29.82 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $27.87 | 2020 | |
| Metuchen Pharmaceuticals | $18.70 | 2019 | |
| Redhill Biopharma INC. | $16.98 | 2020 | |
| Mylan Specialty L.P. | $16.79 | 2019 | |
| Eisai INC. | $16.79 | 2020 | |
| Esperion Therapeutics, INC. | $15.85 | 2020 | |
| Lundbeck LLC | $15.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.42 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.